Your browser is no longer supported. Please, upgrade your browser.
AZN [NASD]
AstraZeneca PLC
Index- P/E38.64 EPS (ttm)1.51 Insider Own0.50% Shs Outstand2.62B Perf Week0.12%
Market Cap154.06B Forward P/E15.69 EPS next Y3.72 Insider Trans0.00% Shs Float2.60B Perf Month2.65%
Income3.98B PEG2.09 EPS next Q0.48 Inst Own16.70% Short Float5.20% Perf Quarter17.55%
Sales27.58B P/S5.59 EPS this Y137.20% Inst Trans6.07% Short Ratio16.78 Perf Half Y19.89%
Book/sh5.50 P/B10.62 EPS next Y31.55% ROA6.20% Target Price63.60 Perf Year12.07%
Cash/sh2.94 P/C19.84 EPS next 5Y18.50% ROE29.20% 52W Range46.48 - 64.94 Perf YTD16.86%
Dividend1.40 P/FCF78.76 EPS past 5Y1.70% ROI12.20% 52W High-10.04% Beta0.57
Dividend %2.40% Quick Ratio0.70 Sales past 5Y1.50% Gross Margin79.00% 52W Low25.69% ATR0.77
Employees76100 Current Ratio0.90 Sales Q/Q15.20% Oper. Margin21.20% RSI (14)64.59 Volatility1.33% 1.28%
OptionableYes Debt/Eq1.40 EPS Q/Q99.20% Profit Margin14.40% Rel Volume0.65 Prev Close57.98
ShortableYes LT Debt/Eq1.24 EarningsApr 30 BMO Payout90.40% Avg Volume8.05M Price58.42
Recom1.50 SMA201.56% SMA505.71% SMA20010.78% Volume5,247,889 Change0.76%
Apr-12-21Downgrade Argus Buy → Hold
Mar-16-21Upgrade Jefferies Hold → Buy
Feb-25-21Upgrade UBS Neutral → Buy
Jan-15-21Initiated Deutsche Bank Buy
Dec-07-20Upgrade Morgan Stanley Equal-Weight → Overweight
Nov-30-20Upgrade UBS Sell → Neutral
Nov-11-20Upgrade HSBC Securities Reduce → Hold
Sep-29-20Initiated Berenberg Buy
Nov-22-19Initiated SVB Leerink Outperform
Oct-25-19Upgrade Liberum Hold → Buy
Apr-02-19Downgrade UBS Neutral → Sell
Feb-05-19Initiated Exane BNP Paribas Outperform
Jan-25-19Upgrade Shore Capital Hold → Buy
Dec-11-18Resumed Jefferies Hold
Oct-09-18Initiated Guggenheim Buy
Aug-16-18Downgrade Jefferies Buy → Hold
Mar-19-18Upgrade Jefferies Hold → Buy
Feb-06-18Reiterated Leerink Partners Mkt Perform $36 → $38
Feb-05-18Reiterated Bernstein Outperform $40 → $42
Jan-18-18Reiterated Leerink Partners Mkt Perform $33 → $36
Jun-25-21 07:12AM  
Jun-24-21 08:55PM  
08:00PM  
02:00PM  
01:29PM  
01:21PM  
11:01AM  
08:43AM  
08:10AM  
05:35AM  
Jun-23-21 01:48PM  
10:52AM  
09:56AM  
05:55AM  
05:46AM  
Jun-22-21 05:20PM  
02:53PM  
02:21PM  
09:28AM  
07:01AM  
05:53AM  
05:22AM  
05:19AM  
Jun-21-21 02:44PM  
11:46AM  
09:50AM  
Jun-20-21 08:00PM  
03:00PM  
Jun-19-21 05:05PM  
Jun-18-21 05:12PM  
02:04PM  
01:19PM  
12:57PM  
10:44AM  
10:14AM  
09:29AM  
09:29AM  
09:26AM  
09:18AM  
09:06AM  
08:12AM  
05:51AM  
03:04AM  
Jun-17-21 11:51PM  
08:00PM  
05:50PM  
05:30PM  
04:47PM  
03:07PM  
10:32AM  
10:27AM  
09:55AM  
06:00AM  
06:00AM  
04:01AM  
03:05AM  
Jun-16-21 08:00PM  
08:00PM  
01:48PM  
10:25AM  
09:57AM  
09:20AM  
06:00AM  
03:27AM  
Jun-15-21 07:47PM  
03:20PM  
02:38PM  
01:10PM  
09:57AM  
08:59AM  
08:21AM  
07:18AM  
06:51AM  
06:11AM  
04:38AM  
02:27AM  
Jun-14-21 08:00PM  
08:00PM  
03:19PM  
01:47PM  
01:00PM  
11:45AM  
10:23AM  
Jun-13-21 09:29AM  
06:37AM  
Jun-11-21 11:11AM  
07:23AM  
07:19AM  
04:51AM  
Jun-10-21 08:00PM  
04:49PM  
01:35PM  
10:34AM  
Jun-09-21 08:00PM  
05:20PM  
04:52PM  
02:53PM  
02:50PM  
03:43AM  
Jun-08-21 08:00PM  
AstraZeneca PLC discovers, develops, manufactures, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, infection, neuroscience, and gastroenterology worldwide. The company's marketed products include Tagrisso, Lynparza, Imfinzi, Enhertu, Koselugo, Lumoxiti, Equidacent, Zoladex, Faslodex, Iressa, Arimidex, Casodex/Cosudex, and others for oncology diseases; Onglyza, Bydureon, Lokelma, Byetta, Qtern, Symlin, and others for cardiovascular, renal, and metabolism diseases; and Symbicort, Pulmicort, Fasenra, Daliresp/Daxas, Duaklir, Tudorza/Eklira, Bevespi, Breztri, Anifrolumab, and others for respiratory and immunology diseases. It also offers other medicines and COVID-19 products, including Synagis, Fluenz Tetra/FluMist Quadrivalent, Seroquel IR/Seroquel XR, Vimovo, Movantik/Moventig, Nexium, Losec/Prilosec, and COVID-19 Vaccine AstraZeneca. The company serves primary care and specialty care physicians through distributors and local representative offices. It has a collaboration agreement with Daiichi Sankyo to develop and commercialize DS-1062 for the treatment of trophoblast cell-surface antigen 2 (TROP2) tumor; AliveCor, Inc. to develop non-invasive potassium monitoring solutions; Massachusetts General Hospital to accelerate digital health solutions; Sanguina on smartphone application study for hemoglobin management in patients with anemia of chronic kidney disease; Alchemab to enhance prostate cancer research; and Proteros biostructures GmbH to discover and develop novel small molecules for the treatment of various types of cancer. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.